MCM
DYN icon

Moore Capital Management’s Dyne Therapeutics DYN Stock Holding History

Moore Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.79M Buy
305,794
+227,029
+288% +$4.22M 0.1% 183
2026
Q1 		$1.43M Buy
+78,765
New +$1.36M 0.03% 336

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Moore Capital Management's DYN Position: Q2 2026 in Review

Moore Capital Management increased its Dyne Therapeutics (DYN) stake by 288% in Q2 2026, buying an estimated $4.22M and bringing the position to 305,794 shares worth $6.79M. The position accounts for 0.1% of the portfolio, ranked #183.

Moore Capital Management first reported a position in DYN in Q1 2026 and has held it in 2 quarters since. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Moore Capital Management held 305,794 shares of Dyne Therapeutics worth $6.79M as of Q2 2026.
  • Moore Capital Management bought 227,029 Dyne Therapeutics shares in Q2 2026, an estimated $4.22M.
  • Dyne Therapeutics made up 0.1% of Moore Capital Management's portfolio in Q2 2026, its #183 holding.
  • Moore Capital Management first reported a position in Dyne Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Moore Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.